Emerging therapeutic targets in breast cancer bone metastasis

Future Oncology

Volumn 6, Issue 1, 2010, Pages 55-74

  Rose, April A N ^a   Siegel, Peter M ^a  

^a MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BALICATIB; BOSUTINIB; CATHEPSIN K; CDX 011; CHEMOKINE RECEPTOR CXCR4; CHEMOKINE RECEPTOR CXCR4 ANTAGONIST; CLODRONIC ACID; COLLAGEN TYPE 1; CR 011; CTCE 9908; DASATINIB; DENOSUMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; GLEMBATUMUMAB VEDOTIN; GLYCOPROTEIN; GLYCOPROTEIN NONMETASTATIC B; IBANDRONIC ACID; INTERLEUKIN 11; INTERSTITIAL COLLAGENASE; N (5 CHLORO 1,3 BENZODIOXOL 4 YL) 7 [2 (4 METHYL 1 PIPERAZINYL)ETHOXY] 5 (TETRAHYDRO 2H PYRAN 4 YLOXY) 4 QUINAZOLINAMINE; ODANACATIB; OSTEOCLAST DIFFERENTIATION FACTOR; PAMIDRONIC ACID; PLACEBO; PLERIXAFOR; PROTEIN TYROSINE KINASE; STROMAL CELL DERIVED FACTOR 1; TRANSCRIPTION FACTOR NFAT; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; XL 228; ZOLEDRONIC ACID;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTHRITIS; BONE DENSITY; BONE METASTASIS; BONE REMODELING; BONE TURNOVER; BREAST CANCER; CANCER GROWTH; CANCER SURVIVAL; CELL DIFFERENTIATION; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DRUG BIOAVAILABILITY; DRUG MEGADOSE; EXTRACELLULAR MATRIX; GENE EXPRESSION PROFILING; HEMATOLOGIC MALIGNANCY; HUMAN; LEUKEMIA; LYMPHOMA; MELANOMA; MICROENVIRONMENT; MULTIPLE MYELOMA; NONHUMAN; OSTEOCLAST; OSTEOLYSIS; OSTEOPOROSIS; PHENOTYPE; PRENYLATION; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN TARGETING; REVIEW; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE; SOLID TUMOR;

ANIMALS; ANTINEOPLASTIC AGENTS; BONE NEOPLASMS; BREAST NEOPLASMS; DRUG DELIVERY SYSTEMS; FEMALE; HUMANS;

EID: 75149164059     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.09.138     Document Type: Review

References (172)

1. Costa L, Major PP: Effect of bisphosphonates on pain and quality of life in patients with bone metastases. Nat. Clin. Pract. Oncol. 6(3), 163-174 (2009).
2. Hess KR, Pusztai L, Buzdar AU, Hortobagyi GN: Estrogen receptors and distinct patterns of breast cancer relapse. Breast Cancer Res. Treat. 78(1), 105-118 (2003).
3. Sotiriou C, Neo SY, McShane LM et al.: Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc. Natl Acad. Sci. USA 100(18), 10393-10398 (2003).
4. Sorlie T, Tibshirani R, Parker J et al.: Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc. Natl Acad. Sci. USA 100(14), 8418-8423 (2003).
5. Sorlie T, Perou CM, Tibshirani R et al.: Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc. Natl Acad. Sci. USA 98(19), 10869-10874 (2001).
6. Smid M, Wang Y, Zhang Y et al.: Subtypes of breast cancer show preferential site of relapse. Cancer Res. 68(9), 3108-3114 (2008).
7. Coleman RE, Guise TA, Lipton A et al.: Advancing treatment for metastatic bone cancer: consensus recommendations from the second Cambridge conference. Clin. Cancer Res. 14(20), 6387-6395 (2008).
8. Nguyen DX, Bos PD, Massague J: Metastasis: from dissemination to organspecific colonization. Nat. Rev. Cancer 9(4), 274-284 (2009).
9. Rose AA, Siegel PM: Breast cancer-derived factors facilitate osteolytic bone metastasis. Bull. Cancer 93(9), 931-943 (2006).
10. Mundy GR: Metastasis to bone: causes, consequences and therapeutic opportunities. Nat. Rev. Cancer 2(8), 584-593 (2002).
11. Quattrocchi CC, Piciucchi S, Sammarra M et al.: Bone metastases in breast cancer: higher prevalence of osteosclerotic lesions. Radiol. Med. 112(7), 1049-1059 (2007).
12. Williams BJ, Fox BD, Sciubba DM et al.: Surgical management of prostate cancer metastatic to the spine. J. Neurosurg. Spine 10(5), 414-422 (2009).
13. Lipton A: Management of bone metastases in breast cancer. Curr. Treat. Options Oncol. 6(2), 161-171 (2005).
14. Green JR: Bisphosphonates: preclinical review. Oncologist 9(Suppl. 4), 3-13 (2004).
15. Clemons MJ, Dranitsaris G, Ooi WS et al.: Phase II trial evaluating the palliative benefit of second-line zoledronic acid in breast cancer patients with either a skeletal-related event or progressive bone metastases despite first-line bisphosphonate therapy. J. Clin. Oncol. 24(30), 4895-4900 (2006).
16. Amir E, Whyne C, Freedman OC et al.: Radiological changes following second-line zoledronic acid treatment in breast cancer patients with bone metastases. Clin. Exp. Metastasis 26(5), 479-484 (2009).
17. Boissier S, Ferreras M, Peyruchaud O et al.: Bisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases. Cancer Res. 60(11), 2949-2954 (2000).
18. Hiraga T, Williams PJ, Ueda A, Tamura D, Yoneda T: Zoledronic acid inhibits visceral metastases in the 4t1/luc mouse breast cancer model. Clin. Cancer Res. 10(13), 4559-4567 (2004).
19. Rachner TD, Singh SK, Schoppet M et al.: Zoledronic acid induces apoptosis and changes the TRAIL/OPG ratio in breast cancer cells. Cancer Lett. (2009) (Epub ahead of print).
20. Woodward JK, Neville-Webbe HL, Coleman RE, Holen I: Combined effects of zoledronic acid and doxorubicin on breast cancer cell invasion in vitro. Anticancer Drugs 16(8), 845-854 (2005).
21. Santini D, Vincenzi B, Galluzzo S et al.: Repeated intermittent low-dose therapy with zoledronic acid induces an early, sustained, and long-lasting decrease of peripheral vascular endothelial growth factor levels in cancer patients. Clin. Cancer Res. 13(15 Pt 1), 4482-4486 (2007).
22. Vincenzi B, Santini D, Dicuonzo G et al.: Zoledronic acid-related angiogenesis modifications and survival in advanced breast cancer patients. J. Interferon Cytokine Res. 25(3), 144-151 (2005).
23. Amir E, Trinkaus M, Simmons CE, Dranitsaris G, Clemons MJ: Vascular endothelial growth factor activity after switching of bisphosphonate treatment for metastatic breast cancer. J. Clin. Pathol. 62(5), 474-476 (2009).
24. Mattarollo SR, Kenna T, Nieda M, Nicol AJ: Chemotherapy and zoledronate sensitize solid tumour cells to vγ9vδ2 t cell cytotoxicity. Cancer Immunol. Immunother. 56(8), 1285-1297 (2007).
25. Dieli F, Vermijlen D, Fulfaro F et al.: Targeting human {γδ} T cells with zoledronate and interleukin2 for immunotherapy of hormonerefractory prostate cancer. Cancer Res. 67(15), 7450-7457 (2007).
26. Kondo M, Sakuta K, Noguchi A et al.: Zoledronate facilitates largescale ex vivo expansion of functional γδ T cells from cancer patients for use in adoptive immunotherapy. Cytotherapy 10(8), 842-856 (2008).
27. Gnant M, Mlineritsch B, Schippinger W et al.: Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N. Engl. J. Med. 360(7), 679-691 (2009).
28. Hirbe AC, Roelofs AJ, Floyd DH et al.: The bisphosphonate zoledronic acid decreases tumor growth in bone in mice with defective osteoclasts. Bone 44(5), 908-916 (2009).
29. Chen T, Berenson J, Vescio R et al.: Pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with bone metastases. J. Clin. Pharmacol. 42(11), 1228-1236 (2002).
30. Lin JH: Bisphosphonates: a review of their pharmacokinetic properties. Bone 18(2), 75-85 (1996).
31. Kaplan RN, Psaila B, Lyden D: Bone marrow cells in the 'pre-metastatic niche': within bone and beyond. Cancer Metastasis Rev. 25(4), 521-529 (2006).
32. Wels J, Kaplan RN, Rafii S, Lyden D: Migratory neighbors and distant invaders: tumor-associated niche cells. Genes Dev. 22(5), 559-574 (2008).
33. Karnoub AE, Dash AB, Vo AP et al.: Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature 449(7162), 557-563 (2007).
34. + myeloid cells that promote metastasis. Cancer Cell 13(1), 23-35 (2008).
35. Kaplan RN, Riba RD, Zacharoulis S et al.: VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature 438(7069), 820-827 (2005).
36. Psaila B, Lyden D: The metastatic niche: adapting the foreign soil. Nat. Rev. Cancer 9(4), 285-293 (2009).
37. Yamada J, Tsuno NH, Kitayama J et al.: Anti-angiogenic property of zoledronic acid by inhibition of endothelial progenitor cell differentiation. J. Surg. Res. 151(1), 115-120 (2009).
38. Ebert R, Zeck S, Krug R et al.: Pulse treatment with zoledronic acid causes sustained commitment of bone marrow derived mesenchymal stem cells for osteogenic differentiation. Bone 44(5), 858-864 (2009).
39. Bendre MS, GaddyKurten D, MonFoote T et al.: Expression of interleukin 8 and not parathyroid hormonerelated protein by human breast cancer cells correlates with bone metastasis in vivo. Cancer Res. 62(19), 5571-5579 (2002).
40. Rose AA, Pepin F, Russo C, Abou Khalil JE, Hallett M, Siegel PM: Osteoactivin promotes breast cancer metastasis to bone. Mol. Cancer Res. 5(10), 1001-1014 (2007).
41. Kang Y, Siegel PM, Shu W et al.: A multigenic program mediating breast cancer metastasis to bone. Cancer Cell 3(6), 537-549 (2003).
42. Bellahcene A, Bachelier R, Detry C, Lidereau R, Clezardin P, Castronovo V: Transcriptome analysis reveals an osteoblast-like phenotype for human osteotropic breast cancer cells. Breast Cancer Res. Treat. 101(2), 135-148 (2007).
43. Zhang XH, Wang Q, Gerald W et al.: Latent bone metastasis in breast cancer tied to src-dependent survival signals. Cancer Cell 16(1), 67-78 (2009).
44. Minn AJ, Kang Y, Serganova I et al.: Distinct organ-specific metastatic potential of individual breast cancer cells and primary tumors. J. Clin. Invest. 115(1), 44-55 (2005).
45. Lu X, Kang Y: Efficient acquisition of dual metastasis organotropism to bone and lung through stable spontaneous fusion between MDA-MB-231 variants. Proc. Natl Acad. Sci. USA 106(23), 9385-9390 (2009).
46. Minn AJ, Gupta GP, Siegel PM et al.: Genes that mediate breast cancer metastasis to lung. Nature 436(7050), 518-524 (2005).
47. Smid M, Wang Y, Klijn JG et al.: Genes associated with breast cancer metastatic to bone. J. Clin. Oncol. 24(15), 2261-2267 (2006).
48. Amir E, Ooi WS, Simmons C et al.: Discordance between receptor status in primary and metastatic breast cancer: an exploratory study of bone and bone marrow biopsies. Clin. Oncol. (R. Coll. Radiol.) 20(10), 763-768 (2008).
49. Broom RJ, Tang PA, Simmons C et al.: Changes in estrogen receptor, progesterone receptor and HER-2/ neu status with time: discordance rates between primary and metastatic breast cancer. Anticancer Res. 29(5), 1557-1562 (2009).
50. Wheeler DL, Iida M, Dunn EF: The role of Src in solid tumors. Oncologist 14(7), 667-678 (2009).
51. Luttrell DK, Lee A, Lansing TJ et al.: Involvement of pp60c-src with two major signaling pathways in human breast cancer. Proc. Natl Acad. Sci. USA 91(1), 83-87 (1994).
52. Muthuswamy SK, Muller WJ: Direct and specific interaction of c-Src with neu is involved in signaling by the epidermal growth factor receptor. Oncogene 11(2), 271-279 (1995).
53. Mcgarrigle D, Huang XY: GPCRs signaling directly through Srcfamily kinases. Sci. STKE 2007(392), pe35 (2007).
54. Muthuswamy SK, Siegel PM, Dankort DL, Webster MA, Muller WJ: Mammary tumors expressing the neu proto-oncogene possess elevated c-Src tyrosine kinase activity. Mol. Cell. Biol. 14(1), 735-743 (1994).
55. Guy CT, Muthuswamy SK, Cardiff RD, Soriano P, Muller WJ: Activation of the c-Src tyrosine kinase is required for the induction of mammary tumors in transgenic mice. Genes Dev. 8(1), 23-32 (1994).
56. Wilson GR, Cramer A, Welman A et al.: Activated cSrc in ductal carcinoma in situ correlates with high tumour grade, high proliferation and HER2 positivity. Br. J. Cancer 95(10), 1410-1414 (2006).
57. Zou D, Yoon HS, Anjomshoaa A et al.: Increased levels of active cSrc distinguish invasive from in situ lobular lesions. Breast Cancer Res. 11(4), R45 (2009).
58. Rucci N, Recchia I, Angelucci A et al.: Inhibition of protein kinase cSrc reduces the incidence of breast cancer metastases and increases survival in mice: Implications for therapy. J. Pharmacol. Exp. Ther. 318(1), 161-172 (2006).
59. Soriano P, Montgomery C, Geske R, BradleyA: Targeted disruption of the cSrc protooncogene leads to osteopetrosis in mice. Cell 64(4), 693-702 (1991).
60. -/-mutant mice. Genes Dev. 11(21), 2835-2844 (1997).
61. Lowe C, Yoneda T, Boyce BF, Chen H, Mundy GR, Soriano P: Osteopetrosis in Srcdeficient mice is due to an autonomous defect of osteoclasts. Proc. Natl Acad. Sci. USA 90(10), 4485-4489 (1993).
62. Miyazaki T, Tanaka S, Sanjay A, Baron R: The role of c-Src kinase in the regulation of osteoclast function. Mod. Rheumatol. 16(2), 68-74 (2006).
63. Koreckij T, Nguyen H, Brown LG, Yu EY, Vessella RL, Corey E: Dasatinib inhibits the growth of prostate cancer in bone and provides additional protection from osteolysis. Br. J. Cancer 101(2), 263-268 (2009).
64. Araujo J, Logothetis C: Targeting Src signaling in metastatic bone disease. Int. J. Cancer 124(1), 1-6 (2009).
65. Finn RS: Targeting Src in breast cancer. Ann. Oncol. 19(8), 1379-1386 (2008).
66. Giles FJ, O'Dwyer M, Swords R: Class effects of tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia. Leukemia 23(10), 1698-1707 (2009).
67. Yin JJ, Selander K, Chirgwin JM et al.: TGF-β signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development. J. Clin. Invest. 103(2), 197-206 (1999).
68. Kang Y, He W, Tulley S et al.: Breast cancer bone metastasis mediated by the Smad tumor suppressor pathway. Proc. Natl Acad. Sci. USA 102(39), 13909-13914 (2005).
69. Deckers M, Van Dinther M, Buijs J et al.: The tumor suppressor smad4 is required for transforming growth factor β-induced epithelial to mesenchymal transition and bone metastasis of breast cancer cells. Cancer Res. 66(4), 2202-2209 (2006).
70. Guo Y, Tiedemann K, Khalil JA, Russo C, Siegel PM, Komarova SV: Osteoclast precursors acquire sensitivity to breast cancer derived factors early in differentiation. Bone 43(2), 386-393 (2008).
71. Guise TA, Chirgwin JM: Transforming growth factor-β in osteolytic breast cancer bone metastases. Clin. Orthop. Relat. Res. (415 Suppl.), S32-S38 (2003).
72. Mourskaia AA, Dong Z, Ng S et al.: Transforming growth factor-β1 is the predominant isoform required for breast cancer cell outgrowth in bone. Oncogene 28(7), 1005-1015 (2009).
73. Korpal M, Yan J, Lu X, Xu S, Lerit DA, KangY: Imaging transforming growth factor-β signaling dynamics and therapeutic response in breast cancer bone metastasis. Nat. Med. 15(8), 960-966 (2009).
74. Bhowmick NA, Chytil A, Plieth D et al.: TGF-β signaling in fibroblasts modulates the oncogenic potential of adjacent epithelia. Science 303(5659), 848-851 (2004).
75. Cheng N, Bhowmick NA, Chytil A et al.: Loss of TGF-β type II receptor in fibroblasts promotes mammary carcinoma growth and invasion through upregulation of TGF-α-, MSPand HGFmediated signaling networks. Oncogene 24(32), 5053-5068 (2005).
76. Yang L, Moses HL: Transforming growth factor β: tumor suppressor or promoter? Are host immune cells the answer? Cancer Res. 68(22), 9107-9111 (2008).
77. Bierie B, Chung CH, Parker JS et al.: Abrogation of TGF-β signaling enhances chemokine production and correlates with prognosis in human breast cancer. J. Clin. Invest. 119(6), 1571-1582 (2009).
78. Yingling JM, Blanchard KL, Sawyer JS: Development of TGF-β signalling inhibitors for cancer therapy. Nat. Rev. Drug Discov. 3(12), 1011-1022 (2004).
79. Biswas S, Criswell TL, Wang SE, ArteagaCL: Inhibition of transforming growth factor-β signaling in human cancer: Targeting a tumor suppressor network as a therapeutic strategy. Clin. Cancer Res. 12(14 Pt1), 4142-4146 (2006).
80. Mourskaia AA, Northey JJ, Siegel PM: Targeting aberrant TGF-β signaling in preclinical models of cancer. Anticancer Agents Med. Chem. 7(5), 504-514 (2007).
81. Bandyopadhyay A, Agyin JK, Wang L et al.: Inhibition of pulmonary and skeletal metastasis by a transforming growth factor-β type I receptor kinase inhibitor. Cancer Res. 66(13), 6714-6721 (2006).
82. Ehata S, Hanyu A, Fujime M et al.: Ki26894, a novel transforming growth factor-b type I receptor kinase inhibitor, inhibits in vitro invasion and in vivo bone metastasis of a human breast cancer cell line. Cancer Sci. 98(1), 127-133 (2007).
83. Padua D, Zhang XH, Wang Q et al.: TGFβ primes breast tumors for lung metastasis seeding through angiopoietinlike 4. Cell 133(1), 66-77 (2008).
84. Baselga J, Rothenberg ML, Tabernero J et al.: TGF-β signallingrelated markers in cancer patients with bone metastasis. Biomarkers 13(2), 217-236 (2008).
85. Kong YY, Yoshida H, Sarosi I et al.: OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymphnode organogenesis. Nature 397(6717), 315-323 (1999).
86. Fili S, Karalaki M, Schaller B: Mechanism of bone metastasis: the role of osteoprotegerin and of the hosttissue microenvironmentrelated survival factors. Cancer Lett. 283(1), 10-19 (2009).
87. Guise TA, Yin JJ, Taylor SD et al.: Evidence for a causal role of parathyroid hormonerelated protein in the pathogenesis of human breast cancermediated osteolysis. J. Clin. Invest. 98(7), 1544-1549 (1996).
88. Jones DH, Nakashima T, Sanchez OH et al.: Regulation of cancer cell migration and bone metastasis by RANKL. Nature 440(7084), 692-696 (2006).
89. Canon JR, Roudier M, Bryant R et al.: Inhibition of RANKL blocks skeletal tumor progression and improves survival in a mouse model of breast cancer bone metastasis. Clin. Exp. Metastasis 25(2), 119-129 (2008).
90. Zheng Y, Zhou H, Brennan K et al.: Inhibition of bone resorption, rather than direct cytotoxicity, mediates the antitumour actions of ibandronate and osteoprotegerin in a murine model of breast cancer bone metastasis. Bone 40(2), 471-478 (2007).
91. Morony S, Capparelli C, Sarosi I, Lacey DL, Dunstan CR, Kostenuik PJ: Osteoprotegerin inhibits osteolysis and decreases skeletal tumor burden in syngeneic and nude mouse models of experimental bone metastasis. Cancer Res. 61(11), 4432-4436 (2001).
92. Chanda D, Isayeva T, Kumar S et al.: Systemic osteoprotegerin gene therapy restores tumorinduced bone loss in a therapeutic model of breast cancer bone metastasis. Mol. Ther. 16(5), 871-878 (2008).
93. Fisher JL, ThomasMudge RJ, Elliott J et al.: Osteoprotegerin overexpression by breast cancer cells enhances orthotopic and osseous tumor growth and contrasts with that delivered therapeutically. Cancer Res. 66(7), 3620-3628 (2006).
94. Kapoor P, Suva LJ, Welch DR, Donahue HJ: Osteoprotegrin and the bone homing and colonization potential of breast cancer cells. J. Cell Biochem. 103(1), 30-41 (2008).
95. Rachner TD, Benad P, Rauner M et al.: Osteoprotegerin production by breast cancer cells is suppressed by dexamethasone and confers resistance against trailinduced apoptosis. J. Cell Biochem. 108(1), 10616 (2009).
96. NevilleWebbe HL, Cross NA, Eaton CL et al.: Osteoprotegerin (OPG) produced by bone marrow stromal cells protects breast cancer cells from trailinduced apoptosis. Breast Cancer Res. Treat. 86(3), 269-279 (2004).
97. Body JJ, Greipp P, Coleman RE et al.: A Phase I study of amgn-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases. Cancer 97(3 Suppl.), 887-892 (2003).
98. Schwarz EM, Ritchlin CT: Clinical development of antirankl therapy. Arthritis Res. Ther. 9(Suppl. 1), S7 (2007).
99. Kostenuik PJ, Nguyen HQ, McCabe J et al.: Denosumab, a fully human monoclonal antibody to RANKL, inhibits bone resorption and increases BMD in knockin mice that express chimeric (murine/human) rankl. J. Bone Miner. Res. 24(2), 182-195 (2009).
100. Cummings SR, San Martin J, McClung MR et al.: Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N. Engl. J. Med. 361(8), 756-765 (2009).
101. Smith MR, Egerdie B, Hernandez Toriz N et al.: Denosumab in men receiving androgendeprivation therapy for prostate cancer. N. Engl. J. Med. 361(8), 745-755 (2009).
102. Kendler DL, Roux C, Benhamou CL et al.: Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy. J. Bone Miner. Res. (2009) (Epub ahead of print).
103. Bekker PJ, Holloway DL, Rasmussen AS et al.: A singledose placebocontrolled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women. J. Bone Miner. Res. 19(7), 1059-1066 (2004).
104. Body JJ, Facon T, Coleman RE et al.: A study of the biological receptor activator of nuclear factor-κb ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer. Clin. Cancer Res. 12(4), 1221-1228 (2006).
105. Lipton A, Steger GG, Figueroa J et al.: Extended efficacy and safety of denosumab in breast cancer patients with bone metastases not receiving prior bisphosphonate therapy. Clin. Cancer Res. 14(20), 6690-6696 (2008).
106. Fizazi K, Lipton A, Mariette X et al.: Randomized Phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates. J. Clin. Oncol. 27(10), 1564-1571 (2009).
107. Henry D, Von Moos R, VadhanRaj S et al.: A doubleblind, randomized study of denosumab versus zoledronic acid for the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. Presented at: ECCO 15 - ESMO 34 European Multidisciplinary Congress. Berlin, Germany, 20-24 September (2009).
108. Stopeck A, Body JJ, Fujiwara Y et al.: Denosumab versus zoledronic acid for the treatment of breast cancer patients with bone metastases: results of a randomized Phase 3 study. Presented at: 2009 ECCO 15 - ESMO 34 European Multidisciplinary Congress. Berlin, Germany, 20-24 September (2009).
109. Balkan W, Martinez AF, Fernandez I, Rodriguez MA, Pang M, Troen BR: Identification of NFAT binding sites that mediate stimulation of cathepsin K promoter activity by RANK ligand. Gene 446(2), 90-98 (2009).
110. Song I, Kim JH, Kim K, Jin HM, Youn BU, Kim N: Regulatory mechanism of NFATC1 in RANKL-induced osteoclast activation. FEBS Lett. 583(14), 2435-2440 (2009).
111. Wilson SR, Peters C, Saftig P, Bromme D: Cathepsin K activitydependent regulation of osteoclast actin ring formation and bone resorption. J. Biol. Chem. 284(4), 2584-2592 (2009).
112. -/-) mice. Bone 44(2), 199-207 (2009).
113. Ishibashi O, Mori Y, Kurokawa T, KumegawaM: Breast cancer cells express Cathepsins B and L but not Cathepsins K or H. Cancer Biochem. Biophys. 17(1-2), 69-78 (1999).
114. Littlewood-Evans AJ, Bilbe G, Bowler WB et al.: The osteoclastassociated protease Cathepsin K is expressed in human breast carcinoma. Cancer Res. 57(23), 5386-5390 (1997).
115. Kleer CG, Bloushtain-Qimron N, Chen YH et al.: Epithelial and stromal Cathepsin K and CXCL14 expression in breast tumor progression. Clin. Cancer Res. 14(17), 5357-5367 (2008).
116. Le Gall C, Bellahcene A, Bonnelye E et al.: A Cathepsin K inhibitor reduces breast cancer induced osteolysis and skeletal tumor burden. Cancer Res. 67(20), 9894-9902 (2007).
117. Deal C: Potential new drug targets for osteoporosis. Nat. Clin. Pract. Rheumatol. 5(1), 20-27 (2009).
118. Stoch SA, Zajic S, Stone J et al.: Effect of the Cathepsin K inhibitor odanacatib on bone resorption biomarkers in healthy postmenopausal women: two doubleblind, randomized, placebocontrolled Phase I studies. Clin. Pharmacol. Ther. 86(2), 175-182 (2009).
119. Jensen AB, Olmeo N, Wynne C et al.: Effect of Cathepsin K inhibition on suppression of bone resorption in women with breast cancer and established bone metastases in a 4week, doubleblind, randomized controlled trial. Presented at: 2008 ASCO Breast Cancer Symposium. Washington DC, USA, 5-7 September (2008).
120. Brown JE, Thomson CS, Ellis SP, Gutcher SA, Purohit OP, Coleman RE: Bone resorption predicts for skeletal complications in metastatic bone disease. Br. J. Cancer 89(11), 2031-2037 (2003).
121. Brown JE, Cook RJ, Major P et al.: Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors. J. Natl Cancer Inst. 97(1), 59-69 (2005).
122. Coleman RE, Major P, Lipton A et al.: Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid. J. Clin. Oncol. 23(22), 4925-4935 (2005).
123. Christopher MJ, Liu F, Hilton MJ, Long F, Link DC: Suppression of CXCL12 production by bone marrow osteoblasts is a common and critical pathway for cytokine-induced mobilization. Blood 114(7), 1331-1339 (2009).
124. Levesque JP, Winkler IG: Mobilization of hematopoietic stem cells: state of the art. Curr. Opin. Organ Transplant. 13(1), 53-58 (2008).
125. Muller A, Homey B, Soto H et al.: Involvement of chemokine receptors in breast cancer metastasis. Nature 410(6824), 50-56 (2001).
126. Cabioglu N, Sahin AA, Morandi P et al.: Chemokine receptors in advanced breast cancer: differential expression in metastatic disease sites with diagnostic and therapeutic implications. Ann. Oncol. 20(6), 1013-1019 (2009).
127. Li YM, Pan Y, Wei Y et al.: Upregulation of CXCR4 is essential for HER2-mediated tumor metastasis. Cancer Cell 6(5), 459-469 (2004).
128. Hassan S, Ferrario C, Saragovi U et al.: The influence of tumor-host interactions in the stromal cell-derived factor-1/CXCR4 ligand/receptor axis in determining metastatic risk in breast cancer. Am. J. Pathol. 175(1), 66-73 (2009).
129. Salvucci O, Bouchard A, Baccarelli A et al.: The role of CXCR4 receptor expression in breast cancer: a large tissue microarray study. Breast Cancer Res. Treat. 97(3), 275-283 (2006).
130. Kang H, Mansel RE, Jiang WG: Genetic manipulation of stromal cell-derived factor-1 attests the pivotal role of the autocrine SDF-1-CXCR4 pathway in the aggressiveness of breast cancer cells. Int. J. Oncol. 26(5), 1429-1434 (2005).
131. Cabioglu N, Summy J, Miller C et al.: CXCL-12/stromal cell-derived factor1a transactivates HER2-neu in breast cancer cells by a novel pathway involving Src kinase activation. Cancer Res. 65(15), 6493-6497 (2005).
132. Liang Z, Yoon Y, Votaw J, Goodman MM, Williams L, Shim H: Silencing of CXCR4 blocks breast cancer metastasis. Cancer Res. 65(3), 967-971 (2005).
133. Smith MC, Luker KE, Garbow JR et al.: CXCR4 regulates growth of both primary and metastatic breast cancer. Cancer Res. 64(23), 8604-8612 (2004).
134. Porcile C, Bajetto A, Barbieri F et al.: Stromal cell-derived factor-1a (SDF-1α/CXCL12) stimulates ovarian cancer cell growth through the EGF receptor transactivation. Exp. Cell Res. 308(2), 241-253 (2005).
135. Huang EH, Singh B, Cristofanilli M et al.: A CXCR4 antagonist CTCE9908 inhibits primary tumor growth and metastasis of breast cancer. J. Surg. Res. 155(2), 231-236 (2008).
136. Richert MM, Vaidya KS, Mills CN et al.: Inhibition of CXCR4 by CTCE9908 inhibits breast cancer metastasis to lung and bone. Oncol. Rep. 21(3), 761-767 (2009).
137. Hotte SJ HH, P Moretto et al.: Final results of a Phase I/II study of CTCE9908, a novel anticancer agent that inhibits CXCR4, in patients with advanced solid cancers. Presented at: 20th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, Geneva, Switzerland, October 21-24 (2008).
138. Hirbe AC, Rubin J, Uluckan O et al.: Disruption of CXCR4 enhances osteoclastogenesis and tumor growth in bone. Proc. Natl Acad. Sci. USA 104(35), 14062-14067 (2007).
139. Zhao GY, Chen XL, Zhao HL, Xie BB, ZhouBC, Zhang YZ: Hydrolysis of insoluble collagen by deseasin MCP01 from deepsea pseudoalteromonas sp. Sm9913: collagenolytic characters, collagenbinding ability of c-terminal polycystic kidney disease domain, and implication for its novel role in deepsea sedimentary particulate organic nitrogen degradation. J. Biol. Chem. 283(52), 36100-36107 (2008).
140. HaralanovaIlieva B, Ramadori G, ArmbrustT: Expression of osteoactivin in rat and human liver and isolated rat liver cells. J. Hepatol. 42(4), 565-572 (2005).
141. Ahn JH, Lee Y, Jeon C et al.: Identification of the genes differentially expressed in human dendritic cell subsets by cDNA subtraction and microarray analysis. Blood 100(5), 1742-1754 (2002).
142. Shikano S, Bonkobara M, Zukas PK, AriizumiK: Molecular cloning of a dendritic cellassociated transmembrane protein, DCHIL, that promotes RGDdependent adhesion of endothelial cells through recognition of heparan sulfate proteoglycans. J. Biol. Chem. 276(11), 8125-8134 (2001).
143. Ripoll VM, Irvine KM, Ravasi T, Sweet MJ, Hume DA: GPNMB is induced in macrophages by IFN-g and lipopolysaccharide and acts as a feedback regulator of proinflammatory responses. J. Immunol. 178(10), 6557-6566 (2007).
144. Chung JS, Bonkobara M, Tomihari M, Cruz PD Jr, Ariizumi K: The DCHIL/syndecan4 pathway inhibits human allogeneic Tcell responses. Eur. J. Immunol. 39(4), 965-974 (2009).
145. Chung JS, Dougherty I, Cruz PD Jr, AriizumiK: Syndecan4 mediates the coinhibitory function of DCHIL on T cell activation. J. Immunol. 179(9), 5778-5784 (2007).
146. Chung JS, Sato K, Dougherty II, Cruz PD Jr, Ariizumi K: DCHIL is a negative regulator of T lymphocyte activation. Blood 109(10), 4320-4327 (2007).
147. Weterman MA, Ajubi N, Van Dinter IM et al.: NMB, a novel gene, is expressed in lowmetastatic human melanoma cell lines and xenografts. Int. J. Cancer 60(1), 73-81 (1995).
148. Rich JN, Shi Q, Hjelmeland M et al.: Bonerelated genes expressed in advanced malignancies induce invasion and metastasis in a genetically defined human cancer model. J. Biol. Chem. 278(18), 15951-15957 (2003).
149. Tse KF, Jeffers M, Pollack VA et al.: Cr011, a fully human monoclonal antibody-auristatin E conjugate, for the treatment of melanoma. Clin. Cancer Res. 12(4), 1373-1382 (2006).
150. Tomihari M, Hwang SH, Chung JS, CruzPD Jr, Ariizumi K: GPNMB is a melanosome-associated glycoprotein that contributes to melanocyte/keratinocyte adhesion in a RGDdependent fashion. Exp. Dermatol. 18(7), 586-595 (2009).
151. Kuan CT, Wakiya K, Dowell JM et al.: Glycoprotein nonmetastatic melanoma protein B, a potential molecular therapeutic target in patients with glioblastoma multiforme. Clin. Cancer Res. 12(7 Pt1), 1970-1982 (2006).
152. Onaga M, Ido A, Hasuike S et al.: Osteoactivin expressed during cirrhosis development in rats fed a cholinedeficient, lamino aciddefined diet, accelerates motility of hepatoma cells. J. Hepatol. 39(5), 779-785 (2003).
153. Ogawa T, Nikawa T, Furochi H et al.: Osteoactivin upregulates expression of MMP3 and MMP9 in fibroblasts infiltrated into denervated skeletal muscle in mice. Am. J. Physiol. Cell Physiol. 289(3), C697-707 (2005).
154. Carter PJ, Senter PD: Antibodydrug conjugates for cancer therapy. Cancer J. 14(3), 154-169 (2008).
155. Pollack VA, Alvarez E, Tse KF et al.: Treatment parameters modulating regression of human melanoma xenografts by an antibody-drug conjugate (CR011-vcMMAE) targeting GPNMB. Cancer Chemother. Pharmacol. 60(3), 423-435 (2007).
156. Qian X, Mills E, Torgov M, Larochelle WJ, Jeffers M: Pharmacologically enhanced expression of GPNMB increases the sensitivity of melanoma cells to the CR011-vcMMAE antibody-drug conjugate. Mol. Oncol. 2(1), 81-93 (2008).
157. Hwu P, Sznol M, Pavlick A et al.: A Phase I/II study of CR011-vcMMAE, an antibodydrug conjugate targeting GPNMB in patients with advanced melanoma. Presented at: 2008 ASCO Annual Meeting. Orlando, FL, USA 29 May-2 June (2009).
158. Peacock N, Saleh M, Bendell J et al.: A Phase I/II study of CR011-VCMMAE, an antibody-drug conjugate, in patients with locally advanced or metastatic breast cancer. Presented at: 2009 ASCO Annual Meeting. Orlando, FL, USA, 29 May-2 June (2009).
159. Safadi FF, Xu J, Smock SL, Rico MC, Owen TA, Popoff SN: Cloning and characterization of osteoactivin, a novel cDNA expressed in osteoblasts. J. Cell Biochem. 84(1), 12-26 (2001).
160. Abdelmagid SM, Barbe MF, Arango-Hisijara I, Owen TA, Popoff SN, Safadi FF: Osteoactivin acts as downstream mediator of BMP-2 effects on osteoblast function. J. Cell Physiol. 210(1), 26-37 (2007).
161. Selim AA, Abdelmagid SM, Kanaan RA et al.: Anti-osteoactivin antibody inhibits osteoblast differentiation and function in vitro. Crit. Rev. Eukaryot. Gene Expr. 13(2-4), 265-275 (2003).
162. Sheng MH, Wergedal JE, Mohan S, Lau KH: Osteoactivin is a novel osteoclastic protein and plays a key role in osteoclast differentiation and activity. FEBS Lett. 582(10), 1451-1458 (2008).
163. Loftus SK, Antonellis A, Matera I et al.: GPNMB is a melanoblast-expressed, MITF-dependent gene. Pigment Cell Melanoma Res. 22(1), 99-110 (2009).
164. Hershey CL, Fisher DE: MITF and TFE3: Members of a B-HLH-zip transcription factor family essential for osteoclast development and function. Bone 34(4), 689-696 (2004).
165. Xian CJ: Roles of epidermal growth factor family in the regulation of postnatal somatic growth. Endocr. Rev. 28(3), 284-296 (2007).
166. Zhu J, Jia X, Xiao G, Kang Y, Partridge NC, Qin L: EGF-like ligands stimulate osteoclastogenesis by regulating expression of osteoclast regulatory factors by osteoblasts: implications for osteolytic bone metastases. J. Biol. Chem. 282(37), 26656-26664 (2007).
167. Lu X, Wang Q, Hu G et al.: Adamts1 and MMP-1 proteolytically engage EGF-like ligands in an osteolytic signaling cascade for bone metastasis. Genes Dev. 23(16), 1882-1894 (2009).
168. Normanno N, De Luca A, Aldinucci D et al.: Gefitinib inhibits the ability of human bone marrow stromal cells to induce osteoclast differentiation: implications for the pathogenesis and treatment of bone metastasis. Endocr. Relat. Cancer 12(2), 471-482 (2005).
169. Normanno N, Gullick WJ: Epidermal growth factor receptor tyrosine kinase inhibitors and bone metastases: different mechanisms of action for a novel therapeutic application? Endocr. Relat. Cancer 13(1), 3-6 (2006).
170. Arteaga CL, Truica CI: Challenges in the development of anti-epidermal growth factor receptor therapies in breast cancer. Semin. Oncol. 31(1 Suppl. 3), 3-8 (2004).
171. Jouret J: 14th CTOS annual meeting. Lancet Oncol. 10(1), 17 (2009).
172. Website201. Clinicaltrials.gov website http://clinicaltrials.gov